Skip to main content
. 2016 Oct 11;38(1):40–50. doi: 10.1093/carcin/bgw106

Figure 1.

Figure 1.

The effect of silibinin against UVB-induced skin carcinogenesis in SKH-1 p53+/+ and p53+/− mice. p53+/+ and p53+/− mice were exposed to UVB alone (90 mJ/cm2) with or without topical application of silibinin (9 mg in 200 µl acetone) either prior to UVB (Sb + UV) or immediately after UVB exposure (UV + Sb) 5 days per week for 25 weeks as detailed in Materials and Methods. Tumor incidences were monitored throughout the study and tumor number and volume were analyzed at the end of 25 weeks. (A) Photographs of SKH-1 p53+/+ and p53+/− mice at the end of the study. The percent tumor incidence in (B) p53+/+ mice and (C) p53+/− mice in UVB alone and silibinin pre- and post-UVB treatment groups. (D) The average tumor number per mouse at the end of the study in p53+/+ and p53+/− mice. (E) The average tumor volume per mouse in each respective group. Grey bars represent p53+/+ mice and black bars represent p53+/− mice. The data shown are mean ± SEM (n = 15). *P < 0.05, **P < 0.001 versus respective UV irradiated group.